News
BCYC
24.85
+1.22%
0.30
2 More Potential Biotech Buyout Targets
Oncology is projected to reach $375 billion in sales by 2027. The oncology space continues to be a hot and active area for M&A activity. Exelixis is one of two smaller companies that appear to be logical buyout targets for larger companies. The company is a mid-cap oncologist with a strong pipeline.
Seeking Alpha · 3d ago
Weekly Report: what happened at BCYC last week (0318-0322)?
Weekly Report · 3d ago
AstraZeneca-Fusion deal reignites radiopharma space
AstraZeneca agreed to acquire its partner Fusion Pharma for $2.4B. The radiopharmaceuticals market is expected to reach more than $13B by 2032. The deal reignites interest in the radiopharma space. Other companies focused on the drug class also traded higher on the news.
Seeking Alpha · 03/19 12:19
Weekly Report: what happened at BCYC last week (0311-0315)?
Weekly Report · 03/18 09:27
Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point
Bicycle Therapeutics plc expects to complete dosing of its open-label phase 1/2 Duravelo-1 study in the 2nd half of 2024. The drug is being advanced for the treatment of patients with metastatic urothelial carcinoma. The company is also advancing other drugs to treat patients with other solid tumor types.
Seeking Alpha · 03/12 16:09
Weekly Report: what happened at BCYC last week (0304-0308)?
Weekly Report · 03/11 09:26
Big Pharma patent cliffs seen fueling oncology M&A this year
Big Pharma patent cliffs seen fueling oncology M&A this year. Around $182B in revenue is at risk over the next four years due to patent expirations. Cantor Fitzgerald sees between five and 17 acquisition deals for oncologists in 2014. The global market for cancer drugs is expected to grow from $180B in 2022 to $323B in 2028.
Seeking Alpha · 03/10 17:08
Tracking Baker Brothers Portfolio - Q4 2023 Update
Seeking Alpha · 03/06 22:09
Bicycle Therapeutics to Present at the AACR Annual Meeting 2024
Bicycle Therapeutics plc accepts three abstracts for poster presentation at the American Association for Cancer Research's Annual Meeting 2024. The company is a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its bicyclic peptide technology. Three abstracts will be presented in San Diego on April 5-10.
Barchart · 03/05 15:35
Weekly Report: what happened at BCYC last week (0226-0301)?
Weekly Report · 03/04 09:27
A fantastic week for Bicycle Therapeutics plc's (NASDAQ:BCYC) 61% institutional owners, one-year returns continue to impress
Institutional investors own over 50% of Bicycle Therapeutics plc. The company's stock price gained 9.5% last week. 52% of the business is held by the top 11 shareholders of the company. With 61% of shares in the company, institutions hold the maximum stake in the firm. The majority of shares are held by hedge funds, but there are other groups of shareholders as well. It's worth looking at the company's history of insider ownership to see if insiders are buying or selling.
Simply Wall St · 02/26 10:24
Weekly Report: what happened at BCYC last week (0219-0223)?
Weekly Report · 02/26 09:29
Radiopharmaceutical market expected to reach ~$14B by 2032
The international market for radiopharmaceuticals is expected to reach $13.67B by 2032. Radiopharma market expected to grow at a compound annual growth rate of 10.2% from 2023. The rising prevalence of cancer and an aging population are among the tailwinds for market growth.
Seeking Alpha · 02/25 17:00
Analysts Are Bullish on These Healthcare Stocks: Edgewise Therapeutics (EWTX), Bicycle Therapeutics (BCYC)
TipRanks · 02/22 05:20
Walmart To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Telsey Advisory Group raised the price target for Walmart Inc. (NYSE:WMT) from $185 to $205. Cantor Fitzgerald cut Palo Alto Networks, Inc. Price target from $400 to $350 on Wednesday. The Middleby Corporation's price target was increased from $164 to $166.
Benzinga · 02/21 18:45
Bicycle Therapeutics Price Target Maintained With a $60.00/Share by Canaccord Genuity
Dow Jones · 02/21 14:06
Canaccord Genuity Reiterates Buy on Bicycle Therapeutics, Maintains $60 Price Target
Benzinga · 02/21 13:57
Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC) and Teladoc (TDOC)
TipRanks · 02/21 13:20
Bicycle Therapeutics: A Strong Buy on Promising Trials and Financial Stability
TipRanks · 02/21 13:09
The Analyst Landscape: 4 Takes On Bicycle Therapeutics
Bicycle Therapeutics (NASDAQ:BCYC) underwent analysis by 4 analysts in the last quarter. The company is a clinical-stage biopharmaceutical company developing a novel class of medicines called Bicycles. The stock has an average price target of $43.25 and is down 11.73% from its 12-month average of $55.00. The firm is developing a drug to treat cancer.
Benzinga · 02/21 13:00
More
Webull provides a variety of real-time BCYC stock news. You can receive the latest news about Bicycle Therapeutics Limited through multiple platforms. This information may help you make smarter investment decisions.
About BCYC
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a class of medicines, which it refers to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are therapeutic modality combining the pharmacology usually associated with a biologic with the manufacturing and pharmacokinetic properties of a small molecule. Its product candidates BT5528, BT8009 and BT1718, are each a Bicycle Toxin Conjugate (BTC). BT5528 is a second-generation BTC designed to target Ephrin type A receptor 2 (EphA2). BT8009 is a second-generation BTC designed to target Nectin-4, a validated tumor antigen. BT1718 is being developed to target tumors that express Membrane Type 1 matrix metalloproteinase (MT1 MMP). Its product candidates BT7480 and BT7455, are each a Bicycle tumor-targeted immune cell agonist (TICA). The Company is also focused on additional therapeutic areas other than its wholly owned oncology portfolio.